![David Scott Geyer](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Provenance du réseau au premier degré de David Scott Geyer
Entité | Type d'entité | Industrie | |
---|---|---|---|
Public Company | Biotechnology | 6 |
Graphique Sociétés connectées au second degré
Relation dans plusieurs entreprises
Sociétés connectées à David Scott Geyer via son réseau personnel
Société | Secteur | Personnes liées | Poste principal |
---|---|---|---|
REGENERON PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Director of Finance/CFO | |
Materials Management, Inc.
![]() Materials Management, Inc. Miscellaneous Commercial ServicesCommercial Services Materials Management, Inc. engages in metal management services. The firm''s services include planning and marketing, risk management and financial services, inventory and metals control, finance and banking, regulatory compliance and trouble-shooting and litigation support. The company was founded by Mike Riess and is headquartered in Greenwich, CT. | Miscellaneous Commercial Services | Director/Board Member | |
IBEX TECHNOLOGIES | Medical Specialties | Founder | |
Genzyme Corp.
![]() Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Medical Specialties | Corporate Officer/Principal | |
AMICUS THERAPEUTICS, INC. | Pharmaceuticals: Major | Chief Executive Officer | |
Pharmasset, Inc.
![]() Pharmasset, Inc. Pharmaceuticals: OtherHealth Technology Pharmasset, Inc. developed drugs to treat viral infections. It focued in the development of oral therapeutics for the treatment of hepatitis C virus (HCV) infection. The company was founded in 1998 and was headquartered in Princeton, NJ. | Pharmaceuticals: Other | Director/Board Member | |
VisionGate, Inc.
![]() VisionGate, Inc. Medical SpecialtiesHealth Technology VisionGate, Inc. provides in-vitro automated 3D cell structure and analysis solutions. It focuses on early detection and prevention of lung cancer. The firm’s attendees include surgeons, medical oncologists, radiation oncologists, pulmonologists, radiologists, pathologists, epidemiologists, basic research scientists, nurses and allied health professionals and patients. The company was founded by Alan C. Nelson and is headquartered in Phoenix, AZ. | Medical Specialties | Director/Board Member | |
OMRIX Biopharmaceuticals, Inc.
![]() OMRIX Biopharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology OMRIX Biopharmaceuticals, Inc. specializes in the manufacture and development of biosurgical and passive immunotherapy products. Its product range encompasses hemostatic, surgical, and immunotherapy solutions. The firm offers solutions for bleeding control, surgical operations, and biodefense applications. The company was founded by Robert Taub in 1995 and is headquartered in Somerville, NJ. | Pharmaceuticals: Major | Chairman | |
RA PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Director/Board Member | |
ULTRAGENYX PHARMACEUTICAL INC. | Pharmaceuticals: Major | Corporate Officer/Principal | |
Sectoral Asset Management, Inc.
![]() Sectoral Asset Management, Inc. Investment ManagersFinance Sectoral Asset Management, Inc. (Sectoral) is an investment management firm headquartered in Montréal, Canada. The firm was founded in 2000 by Jérôme G. Pfund and Michael J. Sjöström. They are a wholly-owned subsidiary of Sectoral Asset Management Holding Ltd. in Hong Kong. Sectoral manages public and private equity healthcare strategies for investors around the world. Their clients include sovereign wealth funds, private banks, and family offices. In addition, they have long-standing sub-advisory relationships with institutional investors in Europe and Asia. | Investment Managers | Corporate Officer/Principal | |
McGill University | College/University | Undergraduate Degree | |
University of California, Los Angeles | College/University | Undergraduate Degree | |
Massachusetts Institute of Technology | College/University | Doctorate Degree | |
Bowdoin College
![]() Bowdoin College Other Consumer ServicesConsumer Services Bowdoin College is an independent, nonsectarian, coeducational residential, undergraduate liberal arts institution founded in 1794. It is located in Brunswick, ME. | College/University | Undergraduate Degree | |
Cornell University
![]() Cornell University Other Consumer ServicesConsumer Services Cornell University is an educational institution that offers undergraduate and post graduate programs. It was founded in 1865 and is based in Ithaca, NY. | College/University | Graduate Degree | |
Zymenex A/S
![]() Zymenex A/S BiotechnologyHealth Technology Zymenex A/S researches and develops therapeutics for life threatening diseases. The firm commercializes novel enzyme replacement therapies for the treatment of life-threatening, rare genetic diseases. The company was founded by Jens Fogh and Pär Gellerfors in 1998 and is headquartered in Hillerod, Denmark. | Biotechnology | Chairman | |
University of Tasmania | College/University | Masters Business Admin | |
Enobia Pharma, Inc.
![]() Enobia Pharma, Inc. Pharmaceuticals: MajorHealth Technology Enobia Pharma, Inc. develops therapies to treat patients with ultra-rare and life-threatening genetic metabolic bone disorders. Its lead product candidate, asfotase alfa or ENB-0040, is a treatment for hypophosphatasia—a life-threatening disease that can cause skeletal deformity, severe muscle weakness and progressive damage to vital organs. The company was founded in 1997 and is headquartered in Montreal, Canada. | Pharmaceuticals: Major | Director/Board Member Chief Executive Officer | |
OrbiMed Advisors Private Equity
![]() OrbiMed Advisors Private Equity Investment ManagersFinance OrbiMed Advisors Private Equity (OrbiMed Advisors Private Equity) is a private equity and venture capital subsidiary of Orbimed Advisors LLC founded in 1993 by Samuel D. Isaly. The firm is headquartered in New York and it has additional offices in San Francisco, Mumbai, Shanghai, Herzliya, Hong Kong and London. | Investment Managers | Corporate Officer/Principal | |
Glycadia, Inc.
![]() Glycadia, Inc. Pharmaceuticals: MajorHealth Technology Glycadia, Inc. is a clinical-stage biopharmaceutical company that develops therapeutics for the prevention and treatment of kidney, eye, cardiovascular, and related diseases resulting from diabetes. The private company is based in Philadelphia, PA, and has subsidiaries in the United States. The company's science is based on recent discoveries concerning the causal role of circulating glycated. Glycadia's experienced R&D team is bringing new scientific discoveries to clinical trials of innovative products for complications of diabetes, including nephropathy, retinopathy, and cardiovascular disease. | Pharmaceuticals: Major | Chairman | |
Canadian Genetic Disease Network | Director/Board Member | ||
Industrial Biotechnology Association of Canada | Director/Board Member | ||
RxFDP | Founder | ||
Gilda's Club New York City, Inc.
![]() Gilda's Club New York City, Inc. Miscellaneous Commercial ServicesCommercial Services Gilda's Club New York City, Inc. provides support services to cancer patients. Its programs include cancer support for all, offsite program, and programs for children and teens with cancer. The company was founded by Gene Wilder, Joanna Bull, Mandy Patinkin, and Joel Siegel in 1995 and is headquartered in New York, NY. | Miscellaneous Commercial Services | Director/Board Member | |
Alliance for Regenerative Medicine
![]() Alliance for Regenerative Medicine Medical/Nursing ServicesHealth Services ARM is a Washington, DC-based multi-stakeholder advocacy organization that promotes global initiatives necessary to facilitate access to life-giving advances in regenerative medicine. The organization promotes legislative, regulatory reimbursement, investment, technical, and other initiatives to accelerate the development of safe and effective regenerative medicine technologies. ARM also works to increase public understand- ing of the field and its potential to transform human healthcare. Prior to the formation of ARM in 2009, there was a need for more coordinated and cohesive advocacy representing the interests of the companies, research institutions, investors and patient groups that comprise the entire regenerative medicine community. Today ARM has more than 140 members and is the leading global advocacy organization in this field. | Medical/Nursing Services | Chairman | |
Lumos Pharma Sub, Inc.
![]() Lumos Pharma Sub, Inc. Medical/Nursing ServicesHealth Services Lumos Pharma Sub, Inc. develops and commercializes a novel treatment for the rare disease creatine transporter deficiency. It focuses on bringing novel therapies to patients afflicted with unmet medical needs in severe, rare, and genetic diseases. The firm's technology LUM-001 is a repurposed small molecule that is a kinetically similar analog of creatine and has shown promising therapeutic potential for the treatment of creatine transporter deficiency. Lumos Pharma was founded by Richard J. Hawkins in 2010 and is headquartered in Austin, TX. | Medical/Nursing Services | Director/Board Member | |
AUDENTES THERAPEUTICS, INC. | Biotechnology | Chief Executive Officer | |
Everylife Foundation for Rare Diseases
![]() Everylife Foundation for Rare Diseases Miscellaneous Commercial ServicesCommercial Services EveryLife Foundation for Rare Diseases is a non-profit organization that aims to advance the development of treatment and diagnostic opportunities for rare disease patients through science-driven public policy. The non-profit company is based in Novato, CA and was founded by Emil D. Kakkis. The foundation provides training, education, resources, and opportunities to make patient voices heard, with the belief that activating the patient advocate can change public policy and save lives. | Miscellaneous Commercial Services | Chief Operating Officer | |
Eloxx Pharmaceuticals Ltd.
![]() Eloxx Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Eloxx Pharmaceuticals Ltd. provides biopharmaceutical research and development services. The firm specializes in the discovery, development, and commercialization of drug compounds for the treatment of genetic diseases. It focuses on the treatment of diseases caused by nonsense mutations, including Cystic fibrosis, Duchene Muscular Dystrophy, Usher syndrome, Ataxia-telangiectasia, Beta thalassemia, and Tay-Sachs Hurler syndrome. Its focus areas encompass clinical drug development and target drugs discovery programs. The company was founded by Silvia Noiman and Shmuel Tuvia in 2013 and is headquartered in Herzliya, Israel. | Pharmaceuticals: Major | Chairman | |
CLEMENTIA PHARMACEUTICALS INC | Pharmaceuticals: Major | Director/Board Member | |
TOBIRA THERAPEUTICS INC | Pharmaceuticals: Major | Director/Board Member | |
JUPITER NEUROSCIENCES, INC. | Pharmaceuticals: Major | Director/Board Member | |
Zingenix Ltd.
![]() Zingenix Ltd. BiotechnologyHealth Technology Zingenix Ltd. provides gene therapy for orphan disorders. The private company is based in Tel Aviv, Israel. | Biotechnology | Chief Executive Officer | |
Parvus Therapeutics, Inc.
![]() Parvus Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Parvus Therapeutics, Inc. manufactures and sells biopharmaceutical products. The private company is based in Calgary, Canada. | Pharmaceuticals: Major | Director/Board Member | |
VOR BIOPHARMA INC. | Biotechnology | Chairman | |
ELOXX PHARMACEUTICALS, INC. | Biotechnology | Chairman | |
Modis Therapeutics, Inc.
![]() Modis Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Modis Therapeutics, Inc. is a biopharmaceutical company, which develops disease-modifying therapies for rare genetic diseases. Its product MT1621 is in clinical development for thymidine kinase 2 deficiency (TK2d), an inherited mitochondrial disease. The company was founded by Peter H. Barber and Daniel D. DiPietro in 2016 and is headquartered in Oakland, CA. | Miscellaneous Commercial Services | Director/Board Member | |
Iris Medicine, Inc.
![]() Iris Medicine, Inc. Medical/Nursing ServicesHealth Services Iris Medicine, Inc. is engaged in providing healthcare services. The company was founded by Keith Gagnon and Megan Blewett and is headquartered in Palo Alto, CA. | Medical/Nursing Services | Chairman | |
Remix Therapeutics, Inc.
![]() Remix Therapeutics, Inc. BiotechnologyHealth Technology Remix Therapeutics, Inc. operates as a biotechnology company. It involves in developing small molecule therapies which are designed to reprogram RNA processing to address the underlying drivers of disease. The company was founded by Pete Smith and is headquartered in Cambridge, MA. | Biotechnology | Chairman | |
501 ACQU | Financial Conglomerates | Director/Board Member | |
Xiconic Pharmaceuticals LLC | Director/Board Member | ||
Nexcella, Inc.
![]() Nexcella, Inc. BiotechnologyHealth Technology Part of Immix Biopharma, Inc., Nexcella, Inc. is a clinical-stage biopharmaceutical company based in Los Angeles, CA. The company is engaged in the discovery and development of novel cell therapies for oncology and other indications. Nexcella's lead candidate, next generation bcma-targeted car-t nxc-201, has produced high response rates in relapsed/refractory al amyloidosis and relapsed/refractory multiple myeloma, and has been awarded orphan drug designation by the FDA in both indications. The company's n-genius platform allows for the discovery, development, and manufacture of cutting-edge cell therapies for patients in need. Expansion into autoimmune indications is planned. | Biotechnology | Director/Board Member |
Statistiques
Internationale
Etats-Unis | 38 |
Canada | 10 |
Israël | 3 |
Danemark | 2 |
Australie | 2 |
Sectorielle
Health Technology | 28 |
Commercial Services | 6 |
Finance | 6 |
Consumer Services | 6 |
Health Services | 4 |
Opérationnelle
Director/Board Member | 37 |
Chairman | 14 |
Independent Dir/Board Member | 13 |
Corporate Officer/Principal | 11 |
Chief Executive Officer | 8 |
Relations les plus connectées
Insiders | |
---|---|
Robert A. Heft | 18 |
Fredric D. Price | 16 |
Vijay Samant | 15 |
Matt Patterson | 14 |
Jeffrey Cooper | 11 |
John Ditton | 8 |
- Bourse
- Insiders
- David Scott Geyer
- Connexions Sociétés